Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients by Ni, Xiaohui et al.
 
Reproducible copy number variation patterns among single
circulating tumor cells of lung cancer patients
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Ni, X., M. Zhuo, Z. Su, J. Duan, Y. Gao, Z. Wang, C. Zong, et al.
2013. “Reproducible Copy Number Variation Patterns Among
Single Circulating Tumor Cells of Lung Cancer Patients.”
Proceedings of the National Academy of Sciences 110 (52)
(December 9): 21083–21088.
Published Version doi:10.1073/pnas.1320659110
Accessed February 16, 2015 9:55:22 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13047661
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Open Access Policy Articles, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#OAP   
 
Reproducible Copy Number Variation Patterns among Single Circulating 
Tumor Cells of Lung Cancer Patients 
Xiaohui  Nia,b,1,  Minglei  Zhuoc,1,  Zhe  Sua,1,  Jianchun  Duanc,1,  Yan  Gaoa,1,  Zhijie  Wangc,1, 
Chenghang Zongb,1,2, Hua Baic, Alec Chapmanb,d, Jun Zhaoc, Liya Xua, Tongtong Anc, Qi Maa, 
Yuyan Wangc, Meina Wuc, Yu Sune, Shuhang Wangc, Zhenxiang Lic, Xiaodan Yangc, Jun Yongb, 
Xiao-Dong Sua, Youyong Luf, Fan Baia,3, X. Sunney Xiea,b,3, and Jie Wangc,3 
aBiodynamic Optical  Imaging Center (BIOPIC), School of Life Sciences, Peking University, 
Beijing 100871, China.  
bDepartment of Chemistry and Chemical Biology, dProgram in Biophysics, Harvard University, 
Cambridge, MA 02138, USA. 
cDepartment of Thoracic Medical Oncology, eDepartment of Pathology, fLaboratory of Molecular 
Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
Peking University Cancer Hospital & Institute, Beijing 100142, China. 
1These authors contributed equally to this work. 
2Present Address: Department of Molecular and Human Genetics, Baylor College of Medicine, 
Houston, TX 77030, USA 
3To  whom  correspondence  should  be  addressed.  Email:  fbai@pku.edu.cn, 
xie@chemistry.harvard.edu, or wangjiepeking@gmail.com. 
Keywords:  Circulating  tumor  cells  |  Multiple  Annealing  and  Looping-Based  Amplification 
Cycles | Copy Number Variations | Metastasis | Cancer Diagnosis 
Classification: Biological Sciences - Genetics   2 
 
Abstract 
Circulating tumor cells (CTCs) enter peripheral blood from primary tumors and seed metastases. 
The genome sequencing of CTCs could offer non-invasive prognosis or even diagnosis, but has 
been hampered by low single cell genome coverage of scarce CTCs. Here we report the use of the 
recently developed Multiple Annealing and Looping-Based Amplification Cycles (MALBAC) for 
whole genome amplification of single CTCs from lung cancer patients. We observed characteristic 
cancer-associated  single  nucleotide  variations  (SNVs)  and  insertions/deletions  (INDELs)  in 
exomes of CTCs. These mutations provided information needed for individualized therapy, such 
as drug resistance and phenotypic transition, but were heterogeneous from cell to cell. In contrast, 
every CTC from an individual patient, regardless of the cancer subtypes, exhibited reproducible 
copy number variation (CNV) patterns, similar to those of the metastatic tumor of the same patient. 
Interestingly, different patients with the same lung cancer adenocarcinoma (ADC) shared similar 
CNV patterns in their CTCs. Even more interestingly, patients of small cell lung cancer (SCLC) 
have CNV patterns distinctly different from those of ADC patients. Our finding suggests  that 
CNVs at certain genomic loci are selected for the metastasis of cancer. The reproducibility of 










In a few milliliters of blood from a cancer patient, one can isolate a few circulating tumor cells 
(CTCs).  Originating  from  the  primary  tumor,  CTCs  seed  metastasis,  which  account  for  the 
majority of cancer-related deaths. We demonstrate the analyses of the whole genome of single 
CTCs, which are highly needed for personalized  treatment. We discovered that copy number 
variations (CNVs), one of the major genomic variations, are specific to cancer types, reproducible 
from cell to cell, and even from patient to patient. We hypothesize that CNVs at certain genomic 
loci  are  selected  for  and  lead  to  metastasis.  Our  work  shows  the  prospect  of  noninvasive 

















As a genomic disease, cancer involves a series of changes in the genome, starting from primary 
tumors, via circulating tumor cells (CTCs), to metastases that cause the majority of mortalities 
(1-3).  These  genomic  alterations  include  copy  number  variations  (CNVs),  single  nucleotide 
variations (SNVs), and insertions/deletions (INDELs). Regardless of the concentrated efforts in 
the past decades, the key driving genomic alterations responsible for metastases are still elusive 
(1).   
For  non-invasive  prognosis  and  diagnosis  of  cancer,  it  is  desirable  to  monitor  genomic 
alterations  through  the  circulation  system.  Genetic  analyses  of  cell-free  DNA  fragments  in 
peripheral blood have been reported (4-6), and recently extended to the whole genome scale (7-9). 
On the other hand, it may be advantageous to analyze CTCs, as they represent intact functional 
cancer cells circulating in peripheral blood (10). While previous studies have shown that CTC 
counting was able to predict progression and overall survival of cancer patients (11,12), genomic 
analyses  of  CTCs  could  provide  more  pertinent  information  for  personalized  therapy  (13). 
However, it is difficult to probe the genomic changes in DNA obtainable from the small number 
of captured CTCs. To meet this challenge, a single cell whole genome amplification (WGA) 
method, MALBAC (14), has been developed to improve the amplification uniformity across the 
entire  genome  over  previous  methods  (15,16),  allowing  precise  determination  of  CNVs  and 
detection of SNVs with a low false positive rate in a single cell. Here we present genomic 
analyses of CTCs from 11 patients (SI Appendix, Table S1) with lung cancer, the leading cause 
of worldwide cancer-related deaths. CTCs were captured with the CellSearch platform using 
antibodies  enrichment  after  fixation,  further  isolated  with  94%  specificity  (Materials  and 
Methods), and then subjected to WGA using MALBAC prior to next generation sequencing. 5 
 
Results 
Single  Cell  Exome  Sequencing  Reveals  SNV/INDEL  Profiles  in  Individual  CTCs  and 
Provides  Information  Needed  for  Personalized  Therapy.  To  detect  SNVs/INDELs,  we 
performed  exome  sequencing  of  24  individual  CTCs  from  4  lung  adenocarcinoma  (ADC) 
patients (Patients 1-4), and compared them with the exomes of their primary and/or metastatic 
tumors. Unlike the other three ADC patients, Patient 1 had undergone a phenotypic transition 
from lung ADC to small cell lung cancer (SCLC) in the liver, which was evidenced by H&E and 
immunohistochemical staining (Fig. 1).   
Bulk exome sequencing identified 54 non-synonymous SNVs and INDELs, mutations that 
cause amino acid changes in proteins, in the primary and metastatic tumors of Patient 1 (Fig. 
2A).  Single  cell  sequencing  of  eight  individual  CTCs  from  Patient  1  showed  a  total  of  44 
non-synonymous SNVs and INDELs (Fig. 2A), each of which was called if a SNV or INDEL in 
a CTC was also detected in two other CTCs or in primary/metastatic tumors in order to eliminate 
false calls due to amplification errors (Materials and Methods). CTCs showed large similarity 
with metastatic but not the primary tumor in SNVs/INDELs. This difference was partially due to 
the low abundance of a given SNV/INDEL in the primary tumor. The Venn diagram showed the 
overlap of non-synonymous SNVs and INDELs across primary tumors, CTCs, and the metastatic 
tumor  in  Patient  1  (Fig.  2B).  Similar  results  have  been  seen  in  the  other  ADC  patients: 
sequencing of Patient 2’s (Patient 3’s) six (five) CTCs identified 106 (145) out of 146 (170) 
non-synonymous SNVs/INDELs in the metastatic tumor. Although a few key SNVs/INDELs 
were  enriched  in  CTCs,  other  point  mutations  (Fig.  2A  and  SI  Appendix,  Fig.  S1)  are 
heterogeneous from cell to cell, as previously reported for solid tumors (16, 17). 6 
 
We now focused on those SNVs/INDELs reported in the Catalogue of Somatic Mutations in 
Cancer  (COSMIC)  (18), which  may play  critical  roles  in  cancer.  In Patient  1, all COSMIC 
mutations that appeared in the primary and/or metastatic tumors have been detected in CTCs, as 
shown in the Venn diagram (Fig. 2C). Among these mutations, one INDEL in the epidermal 
growth factor receptor (EGFR) gene (p.Lys746_Ala750del), which is a target for tyrosine kinase 
inhibitors (TKIs) (19), was identified in the primary and metastatic tumors as well as in CTCs. 
This illustrated an example for the utility of CTC sequencing for identifying therapeutic target 
for personalized treatment.   
The other three COSMIC mutations in the phosphatidylinositol 3-kinase catalytic subunit α 
(PIK3CA)  (p.Glu545Lys),  tumor  protein  53  (TP53)  (p.Thr155Ile),  and  retinoblastoma  (RB1) 
(p.Arg320*) genes were only shared between the liver metastatic tumor and CTCs. The fact that 
these three mutations were not detected in the primary tumor was due to their low abundance. 
Indeed, the use of PCR amplification together with deep sequencing revealed these mutations in 
the primary tumor (SI Appendix, Fig. S2). Regardless of its low abundance in the primary tumor, 
the PIK3CA mutation was detected in 7 of 8 CTCs from Patient 1. The PIK3CA mutation has 
been implicated in  drug resistance of erlotinib (20). Consistently, Patient  1 underwent  rapid 
disease  progression  in  the  liver  metastasis  after  one-month  of  EGFR  TKI  treatment  with 
erlotinib.   
Concurrent mutations in RB1 and TP53 were commonly found in SCLC (21) and have been 
reported to be able to efficiently transform other cells to SCLC (22). We observed RB1 and TP53 
mutations in most of the CTCs in this lung ADC patient. Subsequent needle-biopsy of the liver 
confirmed this transition (Fig. 1). A standard SCLC treatment with etoposide plus cisplatin for 6 
cycles led to a dramatic clinical response. This demonstrated again that CTC sequencing might 7 
 
provide an a priori indication of phenotypic transition and guide the selection of therapeutic 
regimens.   
CNV Patterns of Individual CTCs in Each Patient Are Highly Reproducible. Capitalizing 
on MALBAC’s ability to precisely determine a single cell’s CNVs (14), another major form of 
genetic variations in cancers (23-26), we now examine whether CNVs also exhibit heterogeneity 
from cell to cell. We performed whole-genome sequencing (~0.1x sequencing depth) of CTCs 
from Patient 1. Fig. 3A shows the CNV patterns (segmented with a hidden Markov model) across 
the genome for the eight CTCs of Patient 1, along with the bulk sequencing of her primary and 
metastatic  tumors.  As  a  control  experiment,  the  CNV  patterns  in  the  single  leukocyte  were 
consistent with that of the blood bulk DNA, confirming the uniformity of single cell WGA with 
MALBAC and excluding the possibility that the amplification procedure produced artifacts in 
CNVs.  The  CNV  patterns  in  each  CTC  were  distinctly  different  from  the  normal  single 
leukocyte as shown in SI Appendix, Fig. S3. Surprisingly, we found that all CTCs of Patient 1 
exhibited reproducible gain and loss CNV patterns (an average of 83% of the gain and loss 
regions was shared between any two CTCs).   
Such reproducible global CNV patterns were hidden in bulk sequencing analyses of tumors, 
and only made visible by the high accuracy afforded by MALBAC. The gain and loss regions 
accounted for ~33% and ~8% of the entire genome of CTCs from Patient 1, respectively. The 
CNV patterns of CTCs in Patient 1 resembled more closely those of the metastatic tumor than 
those  of  the  primary  tumor,  raising  the  possibility  that  our  captured  CTCs  came  from  the 
metastatic  tumor.  However,  we  observed  that  EGFR  mutation  was  homozygous  in  bulk 
sequencing of the liver metastatic tumor, but was 50% heterogeneous in the eight CTCs. A 
mixture of wild-type and homozygous mutant genotypes led to an appearance of heterozygous 8 
 
EGFR mutations in the primary tumor. The EGFR mutation frequency in CTCs is close to that in 
the primary tumor, suggesting that a large proportion of CTCs originated from the primary tumor 
and were in an intermediary for metastasis. Furthermore, both primary and metastatic tumors had 
more than 70% of tumor cell content (SI Appendix, Table S1), which excluded the possibility of 
low tumor content in complicating our observation. 
Our finding suggests that during the metastatic process gain and loss of copy numbers at 
certain chromosome regions are selected for cancer cells to enter or survive in the circulation 
system, becoming CTCs. The reproducible CNV patterns might come from the possibility that 
CTCs originated from one subclone in the primary tumor or due to the CTC selection criterion. 
This is unlikely given the heterogeneity of SNVs in single CTCs. 
We examined the reproducibility of the CNV patterns among five other patients (Patients 
2-6) with ADC and one patient (Patient 7) with a mixture of ADC and SCLC in the lung. Again, 
individual CTCs from the same patient showed reproducible CNV patterns (SI Appendix, Figs 
S4-S9). These commonly occurring CNVs were discernible in bulk sequencing of the matched 
metastases (SI Appendix, Figs S4 and S5). The mean CNVs (average over all CTCs in each 
patient) of Patients 2-6 were plotted and segmented in Fig. 3B.   
CTC’s CNV Patterns of Different Patients of the Same ADC Are Similar. Patients 2-6 with 
ADC exhibited almost identical global CNV patterns; an average of 78% of the gain and loss 
regions was shared between any two of these patients. Giving the different clinical characteristics 
of these patients, such as different sexes and ages, the observation of 5 ADC patients with almost 
identical global CNV patterns is striking, providing not only the basis for potential diagnosis of 
ADC via CTCs, but also clues for metastasis.     9 
 
We listed the common copy number gain (in >16 CTCs) and loss (in >7 CTCs) regions, 
together with some important cancer-related genes, of the 5 ADC patients’ CTCs in SI Appendix, 
Table S2. Most of these regions were consistent with the previous statistical analysis of CNVs on 
528 snap-frozen lung adenocarcinoma resection specimens (25). The statistical significance of 
the CNVs in 19 CTCs from these 5 patients is illustrated in SI Appendix, Fig. S10. While CNVs 
spanned a large portion of the chromosome arm, a few genes in the common CNV regions have 
crucial roles in cancer. For example, the gain region in Chromosome 8q contains the c-Myc gene, 
which  is  associated  with  cell  proliferation  and  differentiation.  Likewise,  all  5  ADC  patients 
showed significant gain in Chromosome 5p, which contains the telomerase reverse transcriptase 
(TERT)  gene  that  prevents  the  chromosome  ends  from  degradation.  We  confirmed  the 
amplification of c-Myc gene and TERT gene in a CTC but not in the normal leukocyte with 
digital  PCR  (SI  Appendix,  Fig.  S11).  Four  particular  chromosomal  regions,  3q29,  17q22, 
17q25.3, 20p13, have significant gain in all 19 CTCs of ADC patients 2-6 we sequenced. None 
of the genes in these regions are listed in the Cancer Gene Census (27). The functional roles of 
those genes in metastasis of adenocarcinoma warrant further investigation.     
CTC’s CNV Patterns of Patients with Different Cancer Subtypes Are Dissimilar. Patients 1 
and 7 are different from Patients 2-6 with ADC in that Patient 1 underwent ADC to SCLC 
transition whereas Patient 7 has a mixture of ADC and SCLC in the lung. Interestingly, the CNV 
patterns of Patients 1 and 7 were dissimilar to Patients 2-6 with ADC. Such dissimilarity is 
further proven by hierarchical clustering analyses of their CNV patterns (Fig. 3C), confirming 
the distinction among Patients 1 and 7 and the other five ADC Patients 2-6. In particular, a 
significant response following standard SCLC treatment in Patient 1 was observed, indicating the 
potential for a therapeutic stratification of ADC patients based on CTCs’ CNV patterns.   10 
 
Fig. 4A shows the CNV patterns of CTCs from Patients 8-11 with SCLC without phenotypic 
transitions,  yielding  further  evidence  for  different  cancer  subtypes  exhibiting  distinct  CNV 
patterns. The SCLC patients showed global CNV patterns different from ADC Patients 2-6. An 
average of 42% of the gain and loss regions was shared between any two patients. Inter-patient 
heterogeneity is generally associated with aggressive cancer subtypes, such as is the case for 
SCLC, which is prone to metastasis and has poor prognosis (21). Nevertheless, similarity still 
existed among all ADC and SCLC patients. For example, a common copy number gain spanning 
Chromosome 6p, the human leukocyte antigen (HLA) region, was seen and has been associated 
with the tumor progression (28). Regardless of the heterogeneity among SCLC patients, it is 
important to note that the CNV patterns of individual CTCs from the same patient were still 
reproducible (SI Appendix, Figs S12-S15). The fact that CNV patterns of ADC and SCLC were 
different implied these patterns were cancer subtype-specific, which is of diagnostic significance.       
The  SNVs/INDELs  in  CTCs  Change  During  Treatment,  Whereas  the  CNV  Patterns 
Remain Constant. Important to predict disease progression during drug treatment is the ability 
to monitor the genomic changes of CTCs over time, given that repeat biopsy is not desirable. We 
performed sequential CTC isolation and sequencing on one SCLC patient (Patient 8) at three 
time points: before chemotherapy, after partial response (PR) to first-line chemotherapy with 
etoposide plus platinum, and after disease progression (PD) to second-line chemotherapy with 
topotecan.  Tumor  responses  were  evaluated  according  to  the  RECIST1.1  criteria.  Mutation 
frequencies of SNVs/INDELs across CTCs clearly varied with time (Fig. 4B and SI Appendix, 
Fig.  S16).  For  the  twenty-three  genes  with  significantly  increased  mutation  frequencies  in 
response to chemotherapy, we performed a gene ontology (GO) analysis using GeneCodis 3.0 
(29),  which  revealed  that  six  genes  (ALPK2,  KIF16B,  TP53,  MYH7,  TTLL2,  PAK2)  were 11 
 
enriched in the GO category of “ATP binding” (GO: 0005524) and perhaps responsible for the 
disease progression in this patient. Interestingly, the CTCs’ CNV patterns, at a whole genome 
scale, do not change at different therapeutic stages (Fig. 4C), indicating that the reproducible 
CNV patterns observed were not affected by drug treatment. This further supports that CNVs at 
certain  chromosomal  loci  are  not  only  selected  for  the  onset  of  metastasis  but  also  remain 
constant throughout. 
Discussion 
Monitoring the emergence and alteration of SNVs/INDELs is essential in the process of targeted 
therapy. Consistent with previous work (30), our present work showed that the genomic profiles 
in the metastatic tumors are distinct from those of the primary tumor. Genomic analyses of 
multiple metastatic sites could provide important information related to treatment (31). However, 
it is difficult in clinical practice for most patients to undertake repeat biopsies at multiple tumor 
regions. While the SNVs/INDELs in CTCs are heterogeneous from cell to cell (32), genomic 
analyses of a few CTCs can provide the overall SNVs/INDELs profiles that are present in the 
metastatic tumor tissues during the treatment. Noticeably, some important tumor-related genes, 
including those involved in drug resistance and phenotypic transitions, were frequently mutated 
in  CTCs.  Such  enrichment  may  represent  a  selective  advantage  of  CTCs  to  escape  targeted 
therapy. 
Given the above observations of highly reproducible CNVs in the CTCs of individual (and 
even  different)  patients,  we  hypothesize  that  copy  number  changes  are  the  key  events  of 
metastasis: in the evolution of cancer, gain and loss in copy numbers of certain chromosome 
regions are selected for metastases. The CNVs at a certain combination of gene loci (such as 
c-Myc, TERT, HLA) could alter the gene expression of different pathways, conferring a selective 12 
 
advantage for metastasis. With regard to the underlying selection mechanism, one possibility is 
that cancer cells in the primary tumor with certain CNVs affecting a large-scale of genes could 
invade  the  surrounding  tissues  and  intravasate  more  efficiently.  It  is  also  possible  that  this 
selection happens in the circulation system where CTCs survive the immune surveillance. For 
example, the common gain region in Chromosome 6p could elevate the expression levels of HLA 
proteins and inhibit natural killer (NK) cells (33). This gain could be a critical requirement to 
become  a  CTC,  given the  plenty of NK cells  in  blood  as  compared to their scarcity in  the 
primary tumor.       
A  broad  survey  of  CNV  patterns  in  CTCs  of  different  cancers  is  underway  to  examine 
whether the same degree of reproducibility also occurs in other types of cancers. Although the 
underlying molecular mechanism is yet to be illustrated, the observation of reproducible genomic 
alterations is highly instructive for the understanding of metastasis or even genesis of cancer. 
The  reproducible  CNV  patterns  that  are  characteristic  of  different  cancers  might  allow 
non-invasive cancer diagnostics and classification through sequencing of CTCs.   
 
Materials and Methods 
This study was approved by the institutional ethics committee at Peking University Cancer 
Hospital & Institute and the Committee on the Use of Human Subjects in research at Harvard 
University. Written informed consent was obtained from all patients. A total of 16 patients were 
enrolled. Among them, 11 patients were chosen for sequencing study. A summary of patient 
information was listed in SI Appendix, Table S1. The patient recruitment and clinical information 
were described in SI Appendix. 
CTC  Capture  and  Isolation.  Circulating  tumor  cells  from  7.5  ml  of  blood  sample  were 
captured  with  the  CellSearch@  Epithelial  Cell  Kit  (Veridex,  LLC  a  Johnson  and  Johnson 13 
 
company,  Raritan,  NJ)  using  magnetic  bead  conjugated  to  anti-EpCAM  (Epithelial  Cell 
Adhesion  Molecule)  antibodies.  The  captured  CTCs  were  stained  with  4ʹ, 
6-diamidino-2-phenylindole  (DAPI),  anti-Cytokeratin-Phycoerythrin  and 
anti-CD45-Allophycocyanin antibodies to distinguish cancer cells from carry-over leukocytes. 
We  then  isolated  individual  CTC  (DAPI+,  anti-Cytokeratin+,  anti-CD45-)  and  leukocyte 
(DAPI+, anti-Cytokeratin-, anti-CD45+) under fluorescence microscope by separating individual 
cells manually through micro-pipetting. An additional fluorescein isothiocyanate (FITC) channel 
was added to ensure that fluorescence signal in the anti-Cytokeratin-Phycoerythrin channel was 
not due to other fluorophors. ~30% of CTCs (DAPI+, anti-Cytokeratin+, anti-CD45-) originally 
captured with CellSearch were further excluded as potential false positives by this procedure. 
Each selected CTC was washed multiple times in droplets of UV-exposed water to minimize 
DNA  contamination.  A  total  number  of  72  CTCs  were  sequenced.  Four  CTCs  were  later 
determined to be normal leukocytes based on their CNVs and SNVs/INDEL profiles and were 
excluded from further analyses, which gave a specificity of 94%. 
Whole Genome Amplification. The DNA in single CTC was amplified following the steps in 
Ref.14. Quantitative PCR (qPCR) was performed in 8 randomly selected loci to check for the 
genomic  integrity  of  the  amplification  product.  DNAs  with  7  out  of  8  loci  amplified  with 
reasonable Ct number in qPCR can be used for further sequencing study. 70% CTCs have passed 
this filter.       
Exome Library Preparation and Sequencing. The coding exons plus UTRs were captured 
with SureSelect All Exon V4 (Agilent Technologies, Palo Alto, Calif.) according to Ref. 34 with 
a few modifications. 150 ng – 1 µg of DNA extracted from tumor tissues or amplified from CTC 
by MALBAC was sheared into fragments around 175 bp using the Covaris system (Covaris, 14 
 
Woburn, Massachusetts). The sheared DNA was purified with Agencourt AMPure XP SPRI 
beads (Beckman Coulter, Danvers, MA). The DNA was blunted with 5’-phosphorylated ends 
using the NEB Quick Blunting Kit and ligated to truncated PE P7 adaptors and barcoded P5 
adaptors using NEBNext@ Quick Ligation Module. After clean-up with Agencourt AMPure XP 
SPRI beads and nick fill-in with Bst polymerase Large Fragment (New England Biolabs), the 
DNA fragments with adaptors were enriched by PCR. A total amount of 500 ng DNA pooled 
from  four barcoded libraries was  used for hybridization and post-hybridization amplification 
following  the  manufacture’s  protocol  (SureSelectXT  Target  Enrichment  System  for  Illumina 
Paired-End  Sequencing  Library,  Version  1.3.1,  February  2012,  pp.37-pp.60).  The 
post-hybridization  amplification  product  was  quality  checked  and  sequenced  with  Illumina 
HiSeq  2000/2500  2×100  bp  paired-end  (PE)  reads.  The  coverage  information  of  exome 
sequencing is shown in SI Appendix, Table S3.     
Whole  Genome  Library  Preparation  and  Sequencing.  Libraries  for  whole  genome 
sequencing  were  prepared  from  the  adaptor-ligated  DNA  before  the  pooling  step  in  exome 
library preparation. Enrichment PCR was performed on an aliquot of adaptor-ligated DNA to 
complete the adaptor for Illumina PE sequencing. The PCR product was quality checked and 
sequenced with Illumina HiSeq 2000/2500 2×100 bp PE reads or MiSeq 300 2×150 bp PE reads 
at ~0.1x sequencing depth. The cost for this low sequence depth is affordable for clinical study. 
Exome Sequencing Data Analysis for SNVs/INDELs. Sequencing reads were aligned to the 
UCSC human reference genome (hg19) using the Burrows-Wheeler Aligner (BWA) (35). The 
aligned reads were sorted and merged with Samtools 0.1.18 (36). The INDEL realignment was 
done with the Genome Analysis Toolkit (GATK 2.1-8) (37), and mate pair fix and duplicate 
removal were done with Picard-tools 1.76 (http://Picard.Sourceforge.net). The base quality was 15 
 
recalibrated  and  population  variations  were  detected  by  GATK  using  dbSNP  135 
(http://www.ncbi.nlm.nih.gov/projects/SNP/).  The  functional  effect  of  variants  was  annotated 
with SNPEFF 3.0 (38). Variations that presented in dbSNP 135 and the National Heart, Lung, 
and Blood Institute (NHLBI) Exome Sequencing Project (ESP) but not in COSMIC v61 (18) 
were  filtered  out.  SNVs/INDELs  were  called  for  variations  that  presented  in  tumor  tissue 
specimens or more than two CTCs but not in the matched blood gDNA or single leukocyte. A 
detailed list of the SNVs/INDELs for all four patients is shown in SI Appendix, Table S4, some 
of which were validated by Sanger sequencing. 
Copy  Number  Determination  from  Whole-genome  Sequencing  Data.  The  copy  number 
variant regions were identified according to the procedure in Ref.14. See SI Appendix for the 
procedure. 
Significance Analysis of Gain and Loss Regions in CTCs of ADC Patients. Significance 
analysis of gain and loss regions in all 19 CTCs of ADC patients (Patients 2-6) followed GISTIC 
algorithm (23,39), which is originally intended for CNV data from multiple distinct individuals. 
The sequence data is separated into two sets to calculate p values for gain and loss regions, 
respectively. All the bins that have CNV<2 were re-assigned as 2 for p values calculation in gain 
regions  and  those  that  have  CNV>2  were  re-assigned  as  2  for  p  values  calculation  in  loss 
regions. A value of 0.8 was set for CNV = 0. Then we replaced the copy numbers with an 
amplitude (a = log2
CNV-log2
2). In each data set, we obtained a  G score for every bin in the 
chromosome considering both amplitude and its frequency across all 19 CTCs [G=a × freq.]. A 
null distribution for G score was determined by permuting the data within each CTC. Compared 
with the null distribution, we obtained a p value for each bin in the chromosome. After false 
discovery rate p value adjustment (40), a q value for each bin was assigned. A significant level of 16 
 
10-4.76 for gains and 10-4.18 for losses are given according to the q values of gains and losses in 
eight normal leukocytes; no gain or loss regions have been observed in the normal leukocytes 
based on those significant levels. 
Validation of SNVs and CNVs. Digital PCR, Sanger sequencing, and deep sequencing were 
used  to  validate  SNVs  and  CNVs.  The  detailed  validation  procedure  was  described  in  SI 
Appendix. 
Clustering Analysis. Clustering analysis based  on the whole genome  CNVs  was  applied to 
distinguish  CTCs  from  different  patients  using  algorithms  implemented  in  R  package 
(http://www.R-project.org). First, we normalized sequence reads of each CTC with sequence 
reads  from  all  normal  leukocytes  to  remove  whole  genome  amplification  bias.  We  then 
determined the copy number sequence (a1, a2, a3,…; b1, b2, b3,…;…) at a bin size of 500K along 
the genome by comparing the normalized reads with reads from diploid regions found by HMM. 
The Euclidean distance between pairs of copy number sequence of CTCs was calculated by: 
                                    (1) 
where a and b represent different CTCs. ‘i’ is the index for the bins.   
Based on the above Euclidean distances, Ward’s linkage criterion (41,42) was applied to 
create clusters of CTCs (Fig. 3C). 
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Fig. 1. Primary and metastatic tissues and CTC from Patient 1 who experienced a phenotypic 
transition from ADC to SCLC. The H&E staining and immunohistochemical staining for 22 
 
synaptophysin (SYN) show a typical ADC in the lung (left panel) and a typical SCLC in 
the liver (right panel) (Image magnification: 200x). The CT images show the pre-operative 
primary tumor in  the lower lobe of the  right  lung (yellow  arrow) and  the metastatic 
post-treatment tumor in the right lobe of the liver (blue arrow). In the middle panel, a 
circulating tumor cell is identified by positive staining for DAPI and cytokeratin (Cyto), 
and negative staining for CD45. As a control, a leukocyte is also shown (DAPI+, Cyto-, 
CD45+).  
Fig. 2. Detection of somatic mutations (SNVs and INDELs) in CTCs and primary/metastatic 
tissues of Patient 1. (A) Non-synonymous heterozygous (hetero.) and homozygous (homo.) 
mutations in the lung primary (Pri.) tumor, eight CTCs, and the liver metastatic (Meta.) 
tumor. Blank region represents no sequence coverage. The mutated genes are listed in the 
right column. (B) Venn diagram of the non-synonymous SNVs and INDELs among the 
lung primary tissue, CTCs, and the liver metastatic tissue of Patient 1. (C) Venn diagram of 
the non-synonymous SNVs and INDELs that reported in the COSMIC database.  
Fig. 3. CNVs in CTCs from six patients with ADC and one patient with a mixture of ADC and 
SCLC. (A) All eight CTCs in Patient 1 with reproducible CNV patterns. The copy numbers 
were segmented (blue and red lines) with HMM. (B) CNV patterns of CTCs from 6 ADC 
patients (Patients 1-6) and a patient with a mixture of ADC and SCLC (Patient 7). Patient 1 
experienced a phenotypic transition from ADC in the lung to SCLC in the liver. Patient 7 
was diagnosed as a mixture of ADC and SCLC in the lung. In each patient, sequencing data 
from all CTCs were combined for CNV analyses. (C) Clustering analyses of CTCs based 
on the CNVs. CTCs from Patients 1 and 7 were separated from CTCs from other five ADC 
patients according to the analyses.  23 
 
Fig.  4.  CNVs  and  SNVs/INDELs  of  SCLC.  (A)  Four  SCLC  patients  (Patients  8-11)  with 
heterogeneities in their CNV patterns. In each patient, sequencing data from all CTCs were 
combined for CNV analyses. (B) Fraction of mutation frequency of 152 SNVs/INDELs 
across  CTCs  before  (blue),  and  during  the  first-line  (red)  and  second-line  (green) 
chemotherapy (chemo.) in Patient 8. (C) CTCs from Patient 8 with reproducible CNVs at 
different therapeutic stages. Four CTCs from each stage were shown in this plot (see SI 
Appendix, Figs S12 and S17 for CNVs of all CTCs from this patient). 
 
 
 
 
 
 